at the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identify specifically any questions of fact that are in dispute, and summarize the evidence that would be presented at a hearing.

Comments regarding the application must be received by the Reserve Bank indicated or at the offices of the Board of Governors no later than January 11, 1999.

A. Federal Reserve Bank of Boston(Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. Fleet National Bank, Providence, Rhode Island; to establish Fleet Capital International, Inc., Providence, Rhode Island, which will acquire Sanwa Business Credit (UK) Limited, London, England, and its wholly-owned subsidiary, Sanwa Business Credit (Deutschland) GmbH, Dusseldorf, Germany, and thereby engage in commercial finance activities, pursuant to section 25A of the Federal Reserve Act.

Board of Governors of the Federal Reserve System, December 11, 1998.

Robert deV. Frierson,

Associate Secretary of the Board

[FR Doc. 98–33380 Filed 12–16–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 11, 1999.

A. Federal Reserve Bank of Richmond (A. Linwood Gill III, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. Union Bankshares Corporation, Bowling Green, Virginia; to acquire 100 percent of the voting shares of The Bank of Williamsburg (in organization), Williamsburg, Virginia.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. Old National Bancorp, Evansville, Indiana; to merge with Dulaney Bancorp, Inc., Marshall, Illinois, and thereby indirectly acquire Dulaney National Bank, Marshall, Illinois.

C. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Founders Bancshares, Inc., Dallas, Texas to become a bank holding company by acquiring 100 percent of the voting shares of Founders National Bank-Skillman, Dallas, Texas.

2. Skillman Bancshares, Inc., Dover, Delaware; to become a bank holding company by acquiring 100 percent of the voting shares of Founders National Bank-Skillman, Dallas, Texas.

Board of Governors of the Federal Reserve System, December 11, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–33379 Filed 12–16–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Committee on Employee Benefits of the Federal Reserve System.*

TIME AND DATE: 2:30 p.m., Tuesday, December 22, 1998.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Proposals relating to Federal Reserve System benefits.

2. Proposed interpretation of the Federal Reserve System's Long Term Disability Plan.

3. Any items carried forward from a previously announced meeting.

* * * * *

* The Committee on Employee Benefits considers matters relating to the Retirement, Thrift, Long-Term Disability Income, and Insurance Plans for employees of the Federal Reserve System.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement of this meeting. (The Web site also includes procedural and other information about the meeting.)

Dated: December 15, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–33610 Filed 12–15–98; 2:19 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Ms. Rocio del Carmen Restrepo, University of Illinois at Chicago: Based on an investigation report by the University of Illinois at Chicago, dated March 25, 1998, as well as information obtained by ORI during its oversight review, ORI found that Ms. Restrepo, former research assistant, Department of Psychiatry, University of Illinois at Chicago, engaged in scientific misconduct in clinical research supported by a grant from the National Institute of Mental Health (NIMH), National Institutes of Health (NIH).

Specifically, Ms. Restrepo fabricated research data and submitted the data to the director of a project entitled ''Prenatal Provider-Patient Encounter.'' Data were fabricated in the records of 41 patients, including: dates on which Ms. Restrepo claimed to have conducted interviews in certain clinics; consent forms for patients; questionnaires from patients participating in the project; and false information in her ''Study Daily Logs'' that recorded each day's events.

The fabricated data were not included in any publications.

Ms. Restrepo has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which she has voluntarily agreed, for the three (3) year period beginning December 7, 1998:

(1) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which her participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Restrepo's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 98–33405 Filed 12–16–98; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0339]

FDA Plan for Statutory Compliance; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice of availability that appeared in the **Federal Register** of November 24, 1998 (63 FR 65000). The notice announced the availability of the ''FDA Plan for Statutory Compliance'' which was published in compliance with the Food and Drug Administration Modernization Act of 1997. The document was published with minor errors. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Steven H. Chasin, Office of Planning and Evaluation (HFP–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5207.

SUPPLEMENTARY INFORMATION: In FR Doc. 98–31387 beginning on page 65000 in the **Federal Register** of Tuesday, November 24, 1998, the following corrections are made:

1. On page 65000, in the first column, in the second paragraph of the ''ADDRESSES'' section, in lines eight and nine, ''http://www.fda.gov/opacom/7modact'' is corrected to read ''http://www.fda.gov/opacom/7modact.html''.

2. On page 65039, in the table, under the ''Time frame'' column, under the subheading ''Non-PDUFA'', in line three, the phrase ''and PLA/BLA major supplements'' is removed.

3. On page 65039, in the table, under the ''Overdue'' column, in the 5th entry, ''(CBER)'' is removed; in the same table, in the same column, in the 6th entry ''142'' is added; in the 10th entry, ''52'' is added; and in the 11th entry, ''6'' is added.

4. On page 65039, in the third column following the table, in lines eight and nine, ''http://www.fda.gov/oc/fdama/fdamapln/appenda'' is corrected to read ''http://www.fda.gov/oc/fdama/fdamapln/appenda.htm''.

5. On page 65040, in the first column, in lines 12 and 13, ''http://www.fda.gov/oc/fdama/fdamapln/appendb'' is corrected to read ''http://www.fda.gov/oc/fdama/fdamapln/appendb.htm''; on that same page, in the second column, in lines 4 and 5, ''http://www.fda.gov/oc/fdama/fdamapln/appendc'' is corrected to read ''http://www.fda.gov/oc/fdama/fdamapln/appendc.htm''; and on that same page, in the same column, in lines 15 and 16, ''http://www.fda.gov/oc/fdama/fdamapln/appendd'' is corrected to read''http://www.fda.gov/oc/fdama/fdamapln/appendd.htm''.

Dated: December 8, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–33353 Filed 12–16–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 78N–0280; DESI Nos. 740, 1543, and 7661]

Estrogens for Postpartum Breast Engorgement; Withdrawal of Approval of the Labeled Indication for Postpartum Breast Engorgement in Estrogen-Containing Drug Products; Final Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of estrogen-containing drugs insofar as they are indicated for use in postpartum breast engorgement. The basis for the action is that estrogens are not shown to be safe for that use.

EFFECTIVE DATE: December 17, 1998.

FOR FURTHER INFORMATION CONTACT: David T. Read, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: For many years, estrogen-containing drug products were used to suppress postpartum breast engorgement. By the 1970's, however, the use of estrogens was shown to be associated with an increased risk of puerperal thromboembolism. Moreover, estrogen dosages for the suppression of postpartum breast engorgement were higher than for other labeled indications. The risk of thromboembolism was first evaluated by the FDA Obstetrics and Gynecology Advisory Committee, now called the Advisory Committee for Reproductive Health Drugs (the Committee), on July 15 and 16, 1976. At that time, the Committee recommended that estrogen drug products indicated for the suppression of postpartum breast engorgement contain an insert stating that the risk of thromboembolism should be considered in conjunction with the risk-free alternative of the use of breast binding and mild analgesics. On January 31, 1978, after additional risk evaluation, the Committee recommended that estrogen-containing drug products' indication for the suppression of postpartum breast engorgement be withdrawn.

In a notice of opportunity for hearing (NOOH) published in the **Federal Register** of October 24, 1978 (43 FR 49564), the agency proposed to